Skip to content
Screener

Xeris Biopharma Holdings, Inc. XERS Balance Sheet Statement

Q2 '26Q1 '26Q4 '25Q3 '25Q2 '25
$121.75M+105%$111.75M+91.2%$111.04M+55.0%$91.6M+54.6%$59.29M+2.9%
$58.11M+9.5%$56.3M+21.5%$51.05M+26.3%$53.75M+30.7%$53.05M+25.0%
$80.93M+20.3%$74.23M+40.9%$68.67M+42.5%$67.46M+49.5%$67.28M+56.6%
$274.76M+48.1%$251.68M+53.9%$240.31M+43.3%$224.02M+37.6%$185.58M+8.9%
$4.83M-8.5%$5.03M-4.3%$4.95M-11.1%$4.95M-11.9%$5.28M-9.4%
$22.86M0.0%$22.86M0.0%$22.86M0.0%$22.86M0.0%$22.86M0.0%
$82.66M-11.6%$85.37M-11.3%$88.08M-11.0%$90.79M-10.7%$93.5M-10.4%
$411.91M+23.1%$392.01M+24.3%$383.53M+18.7%$370.19M+15.3%$334.69M+0.9%
$9.34M-1.3%$11.47M+80.5%$3.08M+34.3%$6.53M-12.4%$9.46M+63.2%
$63.78M$0-100%$0-100%$0
$189.57M+99.2%$118.59M+24.7%$109.57M+9.1%$116.2M+27.7%$95.17M+26.1%
$188.81M-13.6%$221.22M+1.6%$220.34M+1.5%$219.47M+1.5%$218.63M-5.1%
$421.64M+19.1%$379M+8.1%$369.84M+4.9%$371.05M+6.2%$353.99M+0.8%
$18K+12.5%$18K+12.5%$17K+13.3%$17K+13.3%$16K+6.7%
-$700.17M-2.5%-$669.07M+1.8%-$671.31M+0.1%-$682.39M-2.3%-$683.01M-4.9%
-$9.73M+49.6%$13.01M+137%$13.69M+146%-$861K+97.0%-$19.3M-0.1%
$411.91M+23.1%$392.01M+24.3%$383.53M+18.7%$370.19M+15.3%$334.69M+0.9%

FAQ

What are Xeris Biopharma Holdings, Inc.'s total assets?
Xeris Biopharma Holdings, Inc. (XERS) holds $411.9M in total assets, up 23.1% year over year.
How much debt does Xeris Biopharma Holdings, Inc. have?
Xeris Biopharma Holdings, Inc. carries $289.4M in total debt against -$9.7M of shareholders' equity, a debt-to-equity ratio of 19.87.
How much cash does Xeris Biopharma Holdings, Inc. have?
Xeris Biopharma Holdings, Inc. holds $121.7M in cash and equivalents.
Can Xeris Biopharma Holdings, Inc. cover its short-term obligations?
Its current ratio is 1.45 — current assets exceed current liabilities.
Where does Xeris Biopharma Holdings, Inc.'s balance sheet data come from?
Every line is extracted from Xeris Biopharma Holdings, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.